ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 754,70
0,40%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Orgenesis Inc (ORGS)

  7. Orgenesis Inc (ORGS) Actualités

ORGS

Orgenesis (ORGS)

Orgenesis Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ORGS
DateHeureSourceTitreSymboleSociété
31/05/202412h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORGSOrgenesis Inc
24/05/202415h16Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ORGSOrgenesis Inc
21/05/202413h00GlobeNewswire Inc.Orgenesis Provides Business Update for the First Quarter of 2024NASDAQ:ORGSOrgenesis Inc
20/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORGSOrgenesis Inc
15/05/202422h01Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ORGSOrgenesis Inc
06/05/202421h30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ORGSOrgenesis Inc
06/05/202421h28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORGSOrgenesis Inc
06/05/202421h26Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORGSOrgenesis Inc
15/04/202423h07GlobeNewswire Inc.Orgenesis Provides Year End Business UpdateNASDAQ:ORGSOrgenesis Inc
10/04/202418h00GlobeNewswire Inc.Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityNASDAQ:ORGSOrgenesis Inc
18/03/202413h30GlobeNewswire Inc.Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceNASDAQ:ORGSOrgenesis Inc
13/03/202413h30GlobeNewswire Inc.Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesNASDAQ:ORGSOrgenesis Inc
04/03/202414h30GlobeNewswire Inc.Orgenesis Inc. Announces $2.3 Million Private PlacementNASDAQ:ORGSOrgenesis Inc
29/02/202414h30GlobeNewswire Inc.Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingNASDAQ:ORGSOrgenesis Inc
31/01/202415h15GlobeNewswire Inc.Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicNASDAQ:ORGSOrgenesis Inc
08/01/202423h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORGSOrgenesis Inc
08/01/202423h36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORGSOrgenesis Inc
14/11/202314h30GlobeNewswire Inc.Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNASDAQ:ORGSOrgenesis Inc
13/11/202322h15GlobeNewswire Inc.Orgenesis Provides Business Update for the Third Quarter of 2023NASDAQ:ORGSOrgenesis Inc
09/11/202313h41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ORGSOrgenesis Inc
08/11/202315h00GlobeNewswire Inc.Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNASDAQ:ORGSOrgenesis Inc
02/11/202313h00GlobeNewswire Inc.Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingNASDAQ:ORGSOrgenesis Inc
31/10/202302h30GlobeNewswire Inc.Orgenesis Announces Withdrawal of Proposed Public OfferingNASDAQ:ORGSOrgenesis Inc
30/10/202321h07GlobeNewswire Inc.Orgenesis Announces Proposed Underwritten Public OfferingNASDAQ:ORGSOrgenesis Inc
21/09/202314h00GlobeNewswire Inc.CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesNASDAQ:ORGSOrgenesis Inc
08/09/202322h05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ORGSOrgenesis Inc
06/09/202313h00GlobeNewswire Inc.Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service SupportNASDAQ:ORGSOrgenesis Inc
11/08/202313h00GlobeNewswire Inc.Orgenesis Provides Business Update for Second Quarter of 2023NASDAQ:ORGSOrgenesis Inc
10/08/202314h30GlobeNewswire Inc.Orgenesis Schedules Second Quarter 2023 Business Update Conference CallNASDAQ:ORGSOrgenesis Inc
13/07/202314h30GlobeNewswire Inc.Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial OfficerNASDAQ:ORGSOrgenesis Inc
 Showing the most relevant articles for your search:NASDAQ:ORGS

Dernières Valeurs Consultées

LSE
44MH
Elenia Ver. 34
NYSE
NPV-A.CL
BIT
UC05M0
Unicredit Bank
COIN
TSTRGBP
USOTC
KRYAF
Kerry (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés